In osteosarcoma, dinaciclib, a pan-cyclin-dependent kinase inhibitor, induced apoptosis by suppressing the expression of MCL-1 and BCL-XL and by inducing the expression of BIM [45]. Here, BCL2L1 is linked to osteosarcoma.